Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors.

Content Provider	Europe PMC
Author	Yamasaki, Hiroshi Futamura, Naonobu Funakawa, Itaru Kohara, Nobuo Yoshimura, Shunsuke Motomura, Masakatsu
Abstract	We herein report two P/Q-type voltage-gated calcium channel (VGCC) antibody-positive Lambert-Eaton myasthenic syndrome (LEMS) patients who responded dramatically to cholinesterase inhibitors. Patient 1, a 76-year-old man, had small-cell lung cancer and developed LEMS during chemotherapy. When symptomatic treatment was started with pyridostigmine, gait disturbance was ameliorated, and his modified Rankin scale decreased from 4 points to 3 points. Patient 2, a 68-year-old man, had cancer-free LEMS. Distigmine bromide was very effective and ameliorated not only his gait disturbance but also autonomic symptoms, and his modified Rankin scale decreased from 2 points to 1 point. Cholinesterase inhibitors alone may be effective in a small portion of LEMS patients.
ISSN	09182918
Volume Number	61
PubMed Central reference number	PMC9038458
Issue Number	7
PubMed reference number	34544947
Journal	Internal Medicine [Intern. Med]
e-ISSN	13497235
DOI	10.2169/internalmedicine.7902-21
Language	English
Publisher	The Japanese Society of Internal Medicine
Publisher Date	2021-09-18
Access Restriction	Open
Rights License	The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). Copyright © 2022 by The Japanese Society of Internal Medicine
Subject Keyword	Lambert-Eaton myasthenic syndrome (LEMS) treatment algorithm electrophysiological examination 3,4-diaminopyridine cholinesterase inhibitors
Content Type	Text
Resource Type	Article
Subject	Internal Medicine